Lixte Biotechnology H -CW25LIXTWPreferred / convertible
13F holders, Q2 2024 (June 30)5holders +1
2new positions
1sold out
1famous investor
$0.06avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Lixte Biotechnology H -CW25 (LIXTW) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were Ethos Financial Group, LLC ($3K), Warberg Asset Management LLC ($2K) and Citadel Advisors ($2K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Lixte Biotechnology H -CW25
- CUSIP
- 539319111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $5K |
| Exits | 1 | $5 |
All 13F filers, Q1 2024 → Q2 2024: 74,462 shares bought and 3,101 shares sold, net +71,361 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Ethos Financial Group, LLC | — | New | 42,105 | $3K |
| Warberg Asset Management LLC | — | Reduce -7.3% | 37,874 | $2K |
| Citadel Advisors | — | New | 32,122 | $2K |
| Clear Street LLC | — | No change | 23,154 | $1K |
| UBS Group AG | — | Add +6.1% | 4,088 | $245 |
"% of holder's portfolio" is LIXTW's weight in each manager's 13F, not the share of Lixte Biotechnology H -CW25 the manager owns.